Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun 5;220(1):57-67.
doi: 10.1093/infdis/jiz071.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

Gaudensia Mutua  1 , Omu Anzala  1 , Kerstin Luhn  2 , Cynthia Robinson  2 , Viki Bockstal  2 , Dickson Anumendem  2 , Macaya Douoguih  2
Affiliations
Clinical Trial

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

Gaudensia Mutua et al. J Infect Dis. .

Abstract

Background: During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo in an African population located in a high-altitude setting in Nairobi, Kenya.

Methods: Healthy adult volunteers were randomized to receive one of four 2-dose vaccination schedules. The first vaccination was administered at baseline (Ad26.ZEBOV or MVA-BN-Filo), followed by the second vaccination with the alternate vaccine after either 28 or 56 days. Each schedule had a placebo comparator group. The primary objective was to assess the safety and tolerability of these regimens.

Results: Seventy-two volunteers were randomized into 4 groups of 18 (15 received vaccine, and 3 received placebo). The most frequent solicited systemic adverse event was headache (frequency, 50%, 61%, and 42% per dose for MVA-BN-Filo, Ad26.ZEBOV, and placebo, respectively). The most frequent solicited local AE was injection site pain (frequency, 78%, 63%, and 33% per dose for MVA-BN-Filo, Ad26.ZEBOV, and placebo, respectively). No differences in adverse events were observed among the different vaccine regimens. High levels of binding and neutralizing anti-Ebola virus glycoprotein antibodies were induced by all regimens and sustained to day 360 after the first dose.

Conclusions: Two-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo was well tolerated and highly immunogenic against Ebola virus glycoprotein.

Clinical trials registration: NCT02376426.

Keywords: Ad26.ZEBOV; Ebola vaccine; MVA-BN-Filo; heterologous 2-dose; safety and immunogenicity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
VAC52150EBL1003 study design. Ad26, Ad26.ZEBOV; MVA, MVA-BN-Filo; TCID50, 50% tissue culture infectious doses; vp, virus particle.
Figure 2.
Figure 2.
Anti–Ebola virus glycoprotein immunoglobulin G binding antibody responses (detected by enzyme-linked immunosorbent assay [ELISA]) binding antibody responses (A) and virus neutralizing antibody (VNA) responses (B) following dose 1 vaccination with Ad26.ZEBOV (Ad26) or MVA-BN-Filo (MVA) and heterologous dose 2 vaccination with MVA or Ad26 on day 29 or day 57, 21 days after dose 2. Data are geometric mean concentration (GMC), for ELISA, and geometric mean 50% inhibitory concentration (IC50), for VNA analysis. Error bars represent 95% confidence intervals. NA, not applicable.
Figure 3.
Figure 3.
Durability of anti–Ebola virus glycoprotein immunoglobulin G binding (A) and neutralizing (B) antibody responses following dose 1 vaccination with Ad26.ZEBOV (Ad26) or MVA-BN-Filo (MVA) and heterologous dose 2 vaccination with MVA or Ad26 on day 29 or day 57. Data are geometric mean values; error bars represent 95% confidence intervals. ELISA, enzyme-linked immunosorbent assay; IC50, 50% inhibitory concentration.
Figure 4.
Figure 4.
Median CD8+ T-cell responses (A) and CD4+ T-cell responses (B) following first dose vaccination with Ad26.ZEBOV (Ad26) or MVA-BN-Filo (MVA) and heterologous second dose vaccination with MVA or Ad26 on day 29 or day 57.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention (CDC). 2014 Ebola outbreak in West Africa—case counts 2016. https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html. Accessed April 2018.
    1. Lambe T, Bowyer G, Ewer KJ. A review of phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? Philos Trans R Soc Lond B Biol Sci 2017; 372:20160295. - PMC - PubMed
    1. Milligan ID, Gibani MM, Sewell R, et al. . Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 2016; 315:1610–23. - PubMed
    1. Winslow RL, Milligan ID, Voysey M, et al. . Immune responses to novel adenovirus type 26 and modified vaccinia virus ankara-vectored Ebola vaccines at 1 year. JAMA 2017; 317:1075–7. - PubMed
    1. Anywaine Z, Whitworth H, Kaleebu P, et al. . Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania. J Infect Dis 2019. In press. - PMC - PubMed

Publication types

Associated data